Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHL TelemedicineLTS:0QMX 45 Buyback Yield % is -30.61 as of Jul. 22, 2026. GuruFocus rates LTS:0QMX with a GF Score™ of 45/100 and a GF Value™ of CHF2.69 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 275 Healthcare Providers & Services companies, SHL Telemedicine ranks worse than 90.55% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for SHL Telemedicine's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0QMX vs VEEV, BTSG, TEM: Buyback Yield % Comparison
For the Health Information Services subindustry, SHL Telemedicine's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SHL Telemedicine Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SHL Telemedicine's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where SHL Telemedicine's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHL Telemedicine (LTS:0QMX) has a Buyback Yield % of -30.61 as of Jul. 22, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on SHL Telemedicine and its competitors. According to the industry distribution chart, SHL Telemedicine ranks #249 out of 275 companies in the Healthcare Providers & Services industry, placing it in the top 90.5%.
Is SHL Telemedicine's Buyback Yield % too high?
SHL Telemedicine's current Buyback Yield % is -30.61. Based on the distribution chart, SHL Telemedicine ranks #249 out of 275 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, SHL Telemedicine has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SHL Telemedicine's Buyback Yield % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, SHL Telemedicine ranks #249 out of 275 companies for Buyback Yield %. This places SHL Telemedicine in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on SHL Telemedicine and its competitors. SHL Telemedicine's current Buyback Yield % is -30.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SHL Telemedicine stock overvalued right now?
Based on GuruFocus' analysis, SHL Telemedicine (LTS:0QMX) is currently considered Possible Value Trap. The stock's GF Value™ is CHF2.69, compared to a current price of CHF1.08 — trading 59.9% below its estimated fair value. The current Buyback Yield % is -30.61. SHL Telemedicine's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For SHL Telemedicine (LTS:0QMX), the current Buyback Yield % is -30.61 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SHL Telemedicine (LTS:0QMX) Overvalued in 2026?
Based on GuruFocus' analysis, SHL Telemedicine stock appears to be undervalued.
The current stock price of CHF1.08 is trading 59.9% below its estimated GF Value™ of CHF2.69.
GuruFocus considers SHL Telemedicine to be Possible Value Trap.
Key valuation signals for LTS:0QMX:
Buyback Yield %: -30.61
GF Value™: CHF2.69 vs. price of CHF1.08 (59.9% below fair value)
No single metric tells the full story. See the LTS:0QMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SHL Telemedicine Ltd develops and markets personal telemedicine solutions. The company consists of the transmission of medical data by an individual, from a remote location to a medical call center, through telecommunication networks. The company provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments are Israel, Europe, and the rest of the world, out of which majority of revenue comes from Israel.
45GF Score
Get the complete analysis for LTS:0QMX
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QMX has been successfully added to your 
